Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Keith Connolly

Orthopaedic Surgery Marquette, MI Medical Doctor

NPI 1811333008 CMS profile 355174

1414 W Fair Ave Ste 190, Marquette, MI 49855

Open in the dashboard

General payments

$1,727

22 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Keith Connolly of Marquette, MI is reported in the CMS Open Payments database as having received $1,727 across 22 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 37th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $191 2
2024 General $456 5
2023 General $8 2
2021 General $295 3
2020 General $94 2
2019 General $683 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keith Connolly
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Keith Connolly were reported at $191. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Keith Connolly Orthopaedic Surgery median Middle half National median
2019 $683 $644 $140–$2,844 $163
2020 $94 $312 $75–$1,860 $114
2021 $295 $520 $117–$2,495 $132
2022 $0 $598 $128–$2,731 $149
2023 $8 $461 $128–$2,264 $160
2024 $456 $497 $134–$2,475 $164
2025 $191 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $794 8 payments
  2. Stryker Corporation $437 4 payments
  3. Abbott Laboratories $155 1 payment
  4. Orthofix Medical, Inc. $127 1 payment
  5. DePuy Synthes Sales Inc. $112 3 payments
  6. Innovation Technologies Inc $74 1 payment
  7. Heraeus Medical, LLC. $15 3 payments
  8. Pacira Pharmaceuticals Incorporated $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,347 19 payments
  2. Education $380 3 payments
Products named General payments · program years 2019–2025
  1. ACCOLADE $377 3 payments
  2. Persona Knees $282 2 payments
  3. Hips-None $194 1 payment
  4. ETERNA $155 1 payment
  5. Tapestry $136 1 payment
  6. Genex $136 1 payment
  7. Cervical-Stim $127 1 payment
  8. Persona Knees $117 1 payment
  9. NCB Instruments/Plates/Screws $117 1 payment
  10. ATTUNE $102 2 payments
  11. Other $487 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

418

Median for Orthopedic Surgery: 203

Drug cost

$1,477

Median for Orthopedic Surgery: $1,433

Branded share of claims

4.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 277 $585
Methylprednisolone Generic 85 $478
Ondansetron Odt Ondansetron Brand 17 $193
Omeprazole Generic 26 $113
Celecoxib Generic 13 $108

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$228,687

Of which drugs: $18,390

Medicare patients

545

Average age 73

Services billed

11,061

358 women, 187 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Diabetes 22%
Depression 21%
Ischemic heart disease 19%
Chronic kidney disease 14%
Osteoporosis 14%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 24 1,680 $8,181
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 22 40 $3,875
Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg J7328 Office 17 6,048 $2,162
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 119 1,208 $861
Injection, ketorolac tromethamine, per 15 mg J1885 Office 82 198 $97

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

22 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record